Alembic Pharmaceuticals Limited is an India-based pharmaceutical company involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). The company was founded in 1907 and is headquartered in Vadodara, India.
Alembic Pharmaceuticals Ltd. is a leading research-driven, integrated pharmaceutical company specializing in generic formulations across diverse platforms. It delivers a diverse and expanding range of generics across chronic segments. The company is recognised as a market leader in India for anti-infective drugs in the macrolides segment.
Alembic's therapeutic areas include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic, and Gynaecology. The company provides:
- Branded Specialty Medicines: In various therapeutic areas such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic.
- Generics Formulations: In oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension.
- Active Pharmaceutical Ingredients (APIs).
Alembic Pharmaceuticals operates state-of-the-art facilities:
- International Generics Manufacturing: Located in Panelav, Karkhadi, and Jarod in Gujarat.
- API Manufacturing: Situated at its three plants in Panelav and Karkhadi in Gujarat.
- India Formulations Manufacturing: A dedicated facility in Sikkim.
The company has 3 R&D and 5 manufacturing facilities in total. Its research and development facilities are located in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). These facilities are approved by regulatory authorities of many developed countries, including the US FDA.
Alembic Pharmaceuticals Ltd has a current market capitalization of ₹19,863 Crore as of June 12, 2025, classifying it as a Mid Cap company.
The company's P/E ratio stands at 34.05 times (as of 12-Jun-2025), a 13% discount to its peers' median range of 38.96 times. The P/B ratio is 3.83 times (as of 12-Jun-2025), a 2% premium to its peers' median range of 3.77 times.
Q4 FY25 Performance:
- Consolidated Net Revenue: ₹1,769.64 crore, a 17% year-on-year (YoY) increase from ₹1,516.98 crore in Q4 FY24.
- Net Profit: ₹156.89 crore, slightly down from ₹178.21 crore YoY due to higher expenses, but an improvement sequentially from ₹138.42 crore in Q3 FY25.
- EBITDA: ₹286 crore, a 9% increase YoY.
- EBITDA Margin: 16%, compared to 17.1% in the same period last year.
- Dividend: Final dividend of ₹11 per equity share of face value ₹2, subject to shareholder approval.
Full Year FY25 Performance:
- Total Revenue: ₹6,714.63 crore, up 7% from ₹6,256.93 crore in FY24.
- Net Profit: ₹583.42 crore, marginally down from ₹615.82 crore YoY, impacted by increased operating costs and tax provisions.
Business Segment Performance (Q4 FY25):
- Domestic India Business: 8% YoY growth to ₹545 crore.
- US Generics Segment: 20% YoY growth to ₹508 crore.
- Ex-US Generics Business: Strong 43% YoY surge, reaching ₹375 crore.
- Q4 FY25 Net Revenue: ₹1,769.64 crore
- Q4 FY25 Net Profit: ₹156.89 crore
- FY25 Total Revenue: ₹6,714.63 crore
- FY25 Net Profit: ₹583.42 crore
- Market Capitalization: ₹19,863 Crore (as of 12-Jun-2025)
- Promoter Holding: 69.7% (as of Mar 2025)
Promoter holding in Alembic Pharmaceuticals Ltd has increased to 69.67% as of March 2025 from 69.61% as of June 2024. The company is led by Chirayu Amin as Chairman and Shaunak Amin as Managing Director.
Alembic Pharmaceuticals has been active in securing regulatory approvals and expanding its product portfolio:
- USFDA Approvals:
- Received USFDA approval for Bosutinib Tablets, used to treat chronic myelogenous leukemia, which positively impacted share prices.
- Received final USFDA approval for its Amlodipine and Atorvastatin Tablets, bringing the total ANDA approvals to 223.
- Announced USFDA approval for Rivaroxaban Tablets in multiple strengths, with a significant market potential of $8,497 million.
- Strategic Acquisition: Alembic's subsidiary acquired Utility Therapeutics for $12 million to market FDA-approved and pipeline UTI drugs in the US.
- Annual General Meeting: The 15th AGM is scheduled for August 5, 2025, with the Annual Report FY25 available online.
Shaunak Amin, Managing Director, highlighted the company's focus on specialty therapies in the India-Branded Business and the outperformance of the Animal Health division. The company aims for strong, consistent growth by deepening engagement with healthcare professionals and expanding its product pipeline.
Alembic Pharmaceuticals plans to focus on cost optimization and operational efficiency to improve margins, investing in technology and process improvements to mitigate rising input costs. Expanding its product portfolio and exploring new markets are key strategies to drive future growth and strengthen its position in the global pharmaceutical market.
